Skip to content

Erasca, Inc. ERAS Quick ratio

Quick ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.3×+0.1×
Eli Lilly logo
Eli LillyLLY
1.1×0.0×
Pfizer logo
PfizerPFE
1.2×0.0×
Amgen logo
AmgenAMGN
+0.1×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
6.8×-6.7×
Tango Therapeutics logo
Tango TherapeuticsTNGX
27.4×+21.1×

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Calculated from Erasca, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s quick ratio?
Erasca, Inc. (ERAS) reported quick ratio of 9.5× in Q1 2026.
How has Erasca, Inc.'s quick ratio changed year-over-year?
Erasca, Inc.'s quick ratio decreased by 22.9% year-over-year, from 12.4× to 9.5×.
What is the long-term trend for Erasca, Inc.'s quick ratio?
Over 5 years (2020 to 2025), Erasca, Inc.'s quick ratio has grown at a 2.7% compound annual growth rate (CAGR), from 8.8× to 10×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.